Assessing the influence of insulin type (ultra-rapid vs rapid insulin) and exercise timing on postprandial exercise-induced hypoglycaemia risk in individuals with type 1 diabetes: a randomised controlled trial

What Was Tested

Researchers studied Insulin Aspart in this randomized controlled trial publication.

The relationship between pre-meal insulin type, exercise timing and the risk of postprandial exercise-induced hypoglycaemia in people living with type 1 diabetes is unknown.

The researchers aimed to evaluate the effects of exercise timing (60 vs 120 min post meal) and different insulin types (aspart vs ultra-rapid aspart) on hypoglycaemic risk.

Who Took Part

According to the abstract, 40 individuals were involved.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

Participants were allocated using sequentially numbered, opaque sealed envelopes.

Participants were masked to their group assignment, and each participant was allocated a unique identification number to ensure anonymisation.

How the Study Was Run

The design is described as randomized and crossover.

Random assignment meant chance, not the researchers, decided who got Insulin Aspart and who got the comparison, which limits bias.

In the crossover set-up each of the individuals took both Insulin Aspart and the comparison in turn, acting as their own control.

The primary outcome was change in blood glucose levels between exercise onset and nadir.

What Was Measured

The subject headings attached to it are Diabetes Mellitus, Type 1, Hypoglycemia, Exercise, Postprandial Period, Blood Glucose, Insulin and Hypoglycemic Agents.

The authors tagged it with the keywords Exercise timing, Hypoglycaemia, Postprandial exercise and Ultra-rapid insulin.

What This Means in Plain Language

The paper is a randomized and crossover study of Insulin Aspart in 40 individuals.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2024 (Diabetologia), a journal based in Germany.

More context: the Insulin Aspart compound page, all human trials.